I can understand the frustration considering the previous delays (beyond CM's control...what can one do when FDA is like that). I think they are trying to communicate more now as things are getting more clear(er). From investors' perspective, we can do what we can do..i.e., basically understand the provided info and equip the management with what is needed to push this forward. I don't think they are going to abuse the blank check shares and whatever they are saying is a possibility when we start seeing the results/NEWS roll out from the trials.
News 
Market Data 
Discover 
AI
